Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...
Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Regeneron of Tarrytown, New York, reported Oct. 31 that its Q3-2024 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.54 billion, a 3 percent increa...
Swiss company Roche reported Oct. 23 that Q3-2024 Vabysmo sales were CHF 1 billion ($1.15 billion, converted on Oct. 23, 2024), a 59 percent increase over CHF 656 million in Q3-2023. The company sa...
Ophthalmic manufacturer revenue in Q2-2024 totaled $11.7 billion. Revenue increased 2.6 percent from the same quarter in 2023 and increased 5.9 percent from Q1-2024. The total includes Market Scope...
Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...
Device makers’ added costs for compliance with the new Medical Device Regulation (MDR) in the European Union (EU) will likely affect the mix of ophthalmic products and companies in the region. Howe...
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...
Ophthalmic manufacturer revenue in Q1-2024 totaled $11.0 billion. Revenue decreased 0.2 percent from the same quarter in 2023 and dropped 1.7 percent from Q4-2023. The total includes Market Scope e...
Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...
AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...
Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...
Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...
J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...
Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
Ophthalmic manufacturer revenue in Q4-2023 totaled $11.2 billion. Revenue increased 0.4 percent from the same quarter in 2022 and increased 1.0 percent from Q3-2023. The total includes Market Scope...
Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...
UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...
Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...
Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...
Regeneron, of Tarrytown, New York, reported Feb. 2 that its 2023 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled $5.9 billion, a 6 percent decline from $6.3 bil...
Swiss company Roche reported Feb. 1 that global sales of Vabysmo for 2023 were CHF 2.36 billion ($2.78 billion, converted Feb. 1, 2024), a 299 percent increase (+324 percent cc) over CHF 591 millio...
Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....
Carl Zeiss Meditec reported Dec. 12 that ophthalmology revenue for is full fiscal year 2022/2023, which ended Sept. 30, was €1.58 billion ($1.67 billion, converted Sept. 30), a 7.3 percent increase...
Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...
Alcon reported Nov. 14 that its Q3-2023 net sales totaled $2.3 billion, an 8 percent increase (+9 percent cc) over $2.1 billion in Q3-2022. Surgical net sales for implantables, consumables, and equ...
UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...
Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...
Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...
Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...
Ophthalmic manufacturer revenue in Q2-2023 totaled $11.4 billion. Most public companies reported above-average revenue in Q2-2023 compared with the past three years, while four public companies had...
Viatris, of Pittsburgh, reported Aug. 7 that its Tyrvaya nasal spray for dry eye accounted for net sales of $10.2 million in Q2-2023. The prescription treatment posted net sales of $6.3 million in ...
Horizon Therapeutics, of Dublin, Ireland, reported Aug. 8 that its Q2-2023 Tepezza net sales totaled $446 million, a 7 percent decrease from $479.8 million in Q2-2022. The company said expansion of...
AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...
Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...
Japan-based Hoya Corporation announced July 31 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2023—the first quarter of its fiscal yea...
Regeneron, of Tarrytown, New York, reported Aug. 3 that its Q2-2023 US revenue for Eylea was $1.5 billion, a 7 decrease from $1.62 billion in Q2-2022. The company attributed the decline to a lower ...
Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.